Overview

Phase III Study of ASP2151 in Herpes Zoster Patients

Status:
Completed
Trial end date:
2015-07-10
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of ASP2151 (200 mg and 400 mg) in comparison with valaciclovir (VACV) 3000 mg in patients with herpes zoster.
Phase:
Phase 3
Details
Lead Sponsor:
Maruho Co., Ltd.
Treatments:
Acyclovir
Valacyclovir